Nofazinlimab (CS1003)+Lenvatinib

Phase 3Small molecule

Nofazinlimab (CS1003)+Lenvatinib is one of 31 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Hepatocellular CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

251 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Nofazinlimab (CS1003)+Lenvatinib

CCStone Pharmaceuticals

Phase 3

1 2

Ibrance

Pfizer

Preclinical

1 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Hepsera

Coreg

2 6

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 7

Vermox

WWim Janssens

Preclinical

1 8

Statin

Bristol-Myers Squibb

Preclinical

1 9

Alcohol

Astellas

Preclinical

—10

Anti-PD-1 Monoclonal Antibody

IiTeos Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting·CCStone Pharmaceuticals·Phase 3·NCT04194775·534 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nofazinlimab (CS1003)+Lenvatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nofazinlimab (CS1003)+Lenvatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nofazinlimab (CS1003)+Lenvatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CStone Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCStone Pharmaceuticals

Nofazinlimab (CS1003)+Lenvatinib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News